Drugs / Cofrogliptin

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT04556851 Sep 2020 → Jan 2022 type 2 diabetes mellitus Sichuan Haisco Pharmaceutical Group Co., Ltd Completed No outcome recorded
Phase 41 trial
Phase 4 NCT07019012 Jul 2025 → Oct 2026 expected type 2 diabetes mellitus Huazhong University of Science and Technology Recruiting No outcome recorded
Phase not applicable2 trials
NCT07460336 May 2026 → Dec 2027 expected latent autoimmune diabetes in adults Second Xiangya Hospital of Central South University Not yet recruiting No outcome recorded
NCT07122102 Oct 2025 → Jun 2027 expected type 2 diabetes mellitus Haisco Pharmaceutical Group Co., Ltd. Not yet recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT06863532 Comparator Mar 2025 → Jun 2026 overdue type 2 diabetes mellitus Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Cofrogliptin cofrogliptin (HSK7653), a novel long-acting dipeptidyl peptidase-4 inhibitor” PMID 39434431 Oct 2024
4

NCT07460336

NCT07122102

NCT07019012

NCT06863532

Known as Cofrogliptina ChEMBL registry synonym — accepted as the source's own label CHEMBL4646510
Known as Cofrogliptine ChEMBL registry synonym — accepted as the source's own label CHEMBL4646510
Known as Haisco hsk 7653 ChEMBL registry synonym — accepted as the source's own label CHEMBL4646510
Known as HSK7653 “cofrogliptin (HSK7653), a novel long-acting dipeptidyl peptidase-4 inhibitor” PMID 39434431 Oct 2024
1

“Cofrogliptin (HSK7653)” NCT07122102

Action Inhibit “Cofrogliptin is a novel, ultra-long-acting DPP-4 inhibitor.” NCT07460336
Modality Small molecule CHEMBL4646510
Route Oral “HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oralNCT04556851